Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio

Journal of Biomedical Science

Wun-Chang Ko⁵  Chi-Ming Chen⁶  Chien-Ming Chen⁴  Cheng-Ying Han⁵  Kuo-Hsien Wang¹  Hsin-Te Hsu³  You-Lan Yang² 

[1] Department of Dermatology, Taipei Medical University Hospital, 252 Wu-Hsing St., Taipei 110, Taiwan;School of Respiratory Therapy, College of Medicine, Taipei Medical University, 250 Wu-Hsing St., Taipei 110, Taiwan;Department of Otolaryngology, Taipei Medical University Hospital, 252 Wu-Hsing St., Taipei 110, Taiwan;Department of Medical Technology, College of Medicine, Taipei Medical University, 250 Wu-Hsing St., Taipei 110, Taiwan;Department of Pharmacology, College of Medicine, Taipei Medical University, 250 Wu-Hsing St., Taipei 110, Taiwan;Department of Medicinal Chemistry, College of Pharmacy, Taipei Medical University, 250 Wu-Hsing St., Taipei 110, Taiwan

关键词: phosphodiesterase-4 inhibitor;    hesperetin-7,3'-O-dimethylether;    cytokine;    chronic obstructive pulmonary disease;    allergic asthma;    Airway hyperresponsiveness;   

Others  :  828992
DOI  :  10.1186/1423-0127-18-84

 received in 2011-09-29, accepted in 2011-11-11,  发布年份 2011

【 摘 要 】

Background

Hesperetin was reported to selectively inhibit phosphodiesterase 4 (PDE4). While hesperetin-7,3'-O-dimethylether (HDME) is a synthetic liposoluble hesperetin. Therefore, we were interested in investigating its selectivity on PDE4 and binding ability on high-affinity rolipram-binding sites (HARBs) in vitro, and its effects on ovalbumin-induced airway hyperresponsiveness in vivo, and clarifying its potential for treating asthma and chronic obstructive pulmonary disease (COPD).

Methods

PDE1~5 activities were measured using a two-step procedure. The binding of HDME on high-affinity rolipram-binding sites was determined by replacing 2 nM [³H]-rolipram. AHR was assessed using the FlexiVent system and barometric plethysmography. Inflammatory cells were counted using a hemocytometer. Cytokines were determined using mouse T helper (Th)1/Th2 cytokine CBA kits, and total immunoglobulin (Ig)E or IgG_2a levels were done using ELISA method. Xylazine (10 mg/kg)/ketamine (70 mg/kg)-induced anesthesia was performed.

Results

HDME revealed selective phosphodiesterase 4 (PDE4) inhibition with a therapeutic (PDE4_H/PDE4_L) ratio of 35.5 in vitro. In vivo, HDME (3~30 μmol/kg, orally (p.o.)) dose-dependently and significantly attenuated the airway resistance (R_L) and increased lung dynamic compliance (C_dyn), and decreased enhanced pause (P_enh) values induced by methacholine in sensitized and challenged mice. It also significantly suppressed the increases in the numbers of total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, and levels of cytokines, including interleukin (IL)-2, IL-4, IL-5, interferon-γ, and tumor necrosis factor-α in bronchoalveolar lavage fluid (BALF) of these mice. In addition, HDME (3~30 μmol/kg, p.o.) dose-dependently and significantly suppressed total and ovalbumin-specific immunoglobulin (Ig)E levels in the BALF and serum, and enhanced IgG_2a level in the serum of these mice.

Conclusions

HDME exerted anti-inflammatory effects, including suppression of AHR, and reduced expressions of inflammatory cells and cytokines in this murine model, which appears to be suitable for studying the effects of drugs on atypical asthma and COPD, and for screening those on typical asthma. However, HDME did not influnce xylazine/ketamine-induced anesthesia. Thus HDME may have the potential for use in treating typical and atypical asthma, and COPD.

【 授权许可】

   
2011 Yang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Lee ME, Markowitz J, Lee JO, Lee H: Crystal structure of phosphodiesterase 4D and inhibitor complex (1). FEBS Lett 2002, 530:53-58.
• [2]Torphy TJ, Cieslinski LB: Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol Pharmacol 1990, 37:206-214.
• [3]Kapui Z, Schaeffer P, Mikus EG, Boronkay E, Gyurky J, Herbert JM, Pascal M: Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs. Arzneimittelforschung 1999, 49:685-693.
• [4]de Boer J, Philpott AJ, van Amsterdam RG, Shahid M, Zaagsma J, Nicholson CD: Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol 1992, 106:1028-1034.
• [5]Silver PJ, Hamel LT, Perrone MH, Bentley RG, Bushover CR, Evans DB: Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol 1988, 150:85-94.
• [6]Kim E, Chun HO, Jung SH, Kim JH, Lee JM, Suh BC, Xiang MX, Rhee CK: Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics. Bioorg Med Chem Lett 2003, 13:2355-2358.
• [7]Giembycz MA: Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 2000, 59:193-212.
• [8]Yen KY: Pharmacology of Common Chinese Medicine (III). Taipei: National Research Institute of Chinese Medicine; 1971.
• [9]Wei D, Ci X, Chu X, Wei M, Hua S, Deng X: Hesperidin suppresses ovalbumin-induced airway inflammation in a mouse allergic asthma model. Inflammation 2011, in press.
• [10]Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, Hakulinen T, Aromaa A: Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002, 76:560-568.
• [11]Ko WC, Shih CM, Lai YH, Chen JH, Huang HL: Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochem Pharmacol 2004, 68:2087-2094.
• [12]Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC: Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 2002, 135:113-118.
• [13]Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC: Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002, 110:1045-1052.
• [14]Gomm AS, Nierenstein M: The exhaustive O-methylation of quercetin. J Am Chem Soc 1931, 53:4408-4411.
• [15]Thompson WJ, Appleman MM: Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971, 10:311-316.
• [16]Ahn HS, Crim W, Romano M, Sybertz E, Pitts B: Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 1989, 38:3331-3339.
• [17]Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA: Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 1986, 29:506-514.
• [18]Reeves ML, Leigh BK, England PJ: The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem J 1987, 241:535-541.
• [19]Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
• [20]Schneider HH, Schmiechen R, Brezinski M, Seidler J: Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 1986, (127:):105-115.
• [21]Zhao Y, Zhang HT, O'Donnell JM: Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J Pharmacol Exp Ther 2003, 305:565-572.
• [22]Kanehiro A, Ikemura T, Makela MJ, Lahn M, Joetham A, Dakhama A, Gelfand EW: Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 2001, 163:173-184.
• [23]Kim DY, Park JW, Jeoung D, Ro JY: Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model. Eur J Pharmacol 2009, 612:98-105.
• [24]Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW: Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997, 156:766-775.
• [25]Winterrowd GE, Chin JE: Flow cytometric detection of antigen-specific cytokine responses in lung T cells in a murine model of pulmonary inflammation. J Immunol Methods 1999, 226:105-118.
• [26]Melgert BN, Postma DS, Geerlings M, Luinge MA, Klok PA, van der Strate BW, Kerstjens HA, Timens W, Hylkema MN: Short-term smoke exposure attenuates ovalbumin-induced airway inflammation in allergic mice. Am J Respir Cell Mol Biol 2004, 30:880-885.
• [27]Busse WW, Lemanske RF Jr: Asthma. N Engl J Med 2001, 344:350-362.
• [28]Bogaert P, Tournoy KG, Naessens T, Grooten J: Where asthma and hypersensitivity pneumonitis meet and differ: noneosinophilic severe asthma. Am J Pathol 2009, 174:3-13.
• [29]Revets H, Pynaert G, Grooten J, De Baetselier P: Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol 2005, 174:1097-1103.
• [30]Vojdani A, Erde J: Regulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I). Evid Based Complement Alternat Med 2006, 3:25-30.
• [31]Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW, Balhorn A, Donaldson DD, Dakhama A, Gelfand EW: The role of IL-13 in established allergic airway disease. J Immunol 2002, 169:6482-6489.
• [32]Vargaftig BB, Singer M: Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. Am J Respir Cell Mol Biol 2003, 28:410-419.
• [33]Tucker J, Fanta CH: Integrative inflammation pharmacology: Asthma. In Principles of Pharmacology-The Pathophysiologic Basis of Drug Therapy. Edited by Golan DE, Tashjian AH Jr, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS. Philadelphia: Lippincott Williams & Wilkins; 2005:695-705.
• [34]Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG: Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996, 183:195-201.
• [35]Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, Humphries LA, Rawlings D, Reynolds H, Vigorito E, Turner M: A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002, 196:753-763.
• [36]Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, Smith AJ, Vanhaesebroeck B: Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 2002, 297:1031-1034.
• [37]Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD: Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 2006, 20:455-465.
• [38]Emson CL, Bell SE, Jones A, Wisden W, McKenzie AN: Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J Exp Med 1998, 188:399-404.
• [39]Snapper CM, Marcu KB, Zelazowski P: The immunoglobulin class switch: beyond "accessibility". Immunity 1997, 6:217-223.
• [40]Stavnezer J: Molecular processes that regulate class switching. Curr Top Microbiol Immunol 2000, 245:127-168.
• [41]Westfall DP, Gerthoffer WT, Webb RC: Vasodilators and nitric oxide synthase. In Human Pharmacology Molecular to Clinical. Edited by Brody TM, Larner J, Minneman KP. St. Louis: Mosby; 1998:239-247.
• [42]Lipworth BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005, 365:167-175.
• [43]Hatzelmann A, Schudt C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001, 297:267-279.
• [44]Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703.
• [45]Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
• [46]Draheim R, Egerland U, Rundfeldt C: Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)- [1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. J Pharmacol Exp Ther 2004, 308:555-563.
• [47]Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C: In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)- [1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003, 307:373-385.
• [48]Hoppmann J, Baumer W, Galetzka C, Hofgen N, Kietzmann M, Rundfeldt C: The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol 2005, 57:1609-1617.
• [49]Giembycz MA: Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008, 155:288-290.
• [50]Pages L, Gavalda A, Lehner MD: PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin Ther Pat 2009, 19:1501-1519.
• [51]Higgs G: Is PDE4 too difficult a drug target? Curr Opin Investig Drugs 2010, 11:495-498.
• [52]Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ: The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 2010, 11:26-34. BioMed Central Full Text
• [53]Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C: An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008, 24:1529-1538.
• [54]Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M, Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME: Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 2010, 28:63-70.
• [55]Jin SL, Richter W, Conti M: Insights into the physiological functions of PDE4 from knockout mice. In Cyclic Nucleotide Phosphodiesterases in Health and Disease. Edited by Beavo JA, Francis SH, Houslay MD. Boca Raton: CRC Press; 2007:323-346.
• [56]Fan CK: Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006, 533:110-117.
• [57]Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC: PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 2001, 40:262-269.